Natural variability of NS3 protease in patients infected with genotype 4 hepatitis C virus (HCV): implications for antiviral treatment using specifically targeted antiviral therapy for HCV

Journal of Infectious Diseases

Volumn 200, Issue 4, 2009, Pages 524-527

  Akhavan, S ^a   Schnuriger, A ^a   Lebray, P ^b   Benhamou, Y ^b   Poynard, T ^b   Thibault, V ^a,c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b CNRS   (France)

^c Laboratoire de Virologie CERVI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; C16T PROTEIN; NONSTRUCTURAL PROTEIN 3; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; V36L PROTEIN; VIRUS PROTEIN; NS3 PROTEIN, HEPATITIS C VIRUS;

ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG SENSITIVITY; DRUG TARGETING; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; METAL BINDING; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; AMINO ACID SEQUENCE; CHEMISTRY; CLASSIFICATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULAR GENETICS; PHYLOGENY; PHYSIOLOGY; POLYMERASE CHAIN REACTION;

AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; GENE EXPRESSION REGULATION, VIRAL; GENETIC VARIATION; GENOTYPE; HEPACIVIRUS; HUMANS; MOLECULAR SEQUENCE DATA; PHYLOGENY; POLYMERASE CHAIN REACTION; VIRAL NONSTRUCTURAL PROTEINS;

EID: 69149104607     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/600893     Document Type: Article

References (15)

1. Kamal SM, El Kamary SS, Shardell MD, et al. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: the role of rapid and early virologie response. Hepatology 2007; 46: 1732-1740
2. 2. Roulot D, Bourcier V, Grando V, et al. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J Viral Hepat 2007; 14:460-467 (Pubitemid 46944469)
3. 3. López-Labrador FX, Moya A, González-Candelas E Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates. Antivir Ther 2008; 13: 481-494 (Pubitemid 352016711)
4. 4. Laperche S, Lunel F, Izopet J, et al. Comparison of hepatitis C virus NS5b and 5' noncoding gene sequencing methods in a multicenter study. J Clin Microbiol 2005; 43:733-739 (Pubitemid 40256027)
5. Tarn ura K, Dudley J, Nei M, Kumar S. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 2007; 24:1596-1599
6. WebLogo 3. Available at: http://weblogo.threeplusone.com. Accessed 8 June 2009.
7. 7. Cholongitas E, Papatheodoridis GV. Review article: novel therapeutic options for chronic hepatitis C. Aliment Pharmacol Ther 2008; 27: 866-884 (Pubitemid 351551986)
8. 8. Reiser M, Hinrichsen H, Benhamou Y, et al. Antiviral efficacy of NS3serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology 2005;41:832-835 (Pubitemid 40462946)
9. 9. Tong X, Guo Z, Wright-Minogue J, et al. Impact of naturally occurring variants of HCV protease on the binding of different classes of protease inhibitors. Biochemistry 2006;45:1353-1361 (Pubitemid 43214800)
10. Bartels DJ, Zhou Y, Zhang EZ, et al. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J Infect Dis 2008; 198:800-807
11. Kuntzen T, Timm J, Berical A, et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 2008;48:1769-1778
12. Zhou Y, Bartels DJ, Hanzelka BL, et al. Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother 2008;52:110-120
13. Tong X, Bogen S, Chase R, et al. Characterization of resistance mutations against HCV ketoamide protease inhibitors. Antiviral Res 2008; 77: 177-185
14. 14. Yang W, Zhao Y, Fabrycki J, et al. Selection of replicón variants resistant to ACH-806, a novel hepatitis C virus inhibitor with no cross-resistance to NS3 protease and NS5B polymerase inhibitors. Antimicrob Agents Chemother 2008; 52:2043-2052 (Pubitemid 351758541)
15. 15. Simmonds P, Bukh J, Combet Q et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005;42:962-973 (Pubitemid 41401136)